NO20110582L - Mutasjon av parkingen, preparater, fremgangsmater og anvendelser - Google Patents

Mutasjon av parkingen, preparater, fremgangsmater og anvendelser

Info

Publication number
NO20110582L
NO20110582L NO20110582A NO20110582A NO20110582L NO 20110582 L NO20110582 L NO 20110582L NO 20110582 A NO20110582 A NO 20110582A NO 20110582 A NO20110582 A NO 20110582A NO 20110582 L NO20110582 L NO 20110582L
Authority
NO
Norway
Prior art keywords
gene
parkin
exons
deletion
amplifying
Prior art date
Application number
NO20110582A
Other languages
English (en)
Other versions
NO333907B1 (no
Inventor
Sylvain Ricard
Alexis Brice
Nacer Eddine Abbas
Patrice Denefle
Christophe Lucking
Sandrine Buoley
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9814524A external-priority patent/FR2786199B1/fr
Priority claimed from FR9910140A external-priority patent/FR2797272B1/fr
Publication of NO20110582L publication Critical patent/NO20110582L/no
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO333907B1 publication Critical patent/NO333907B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20110582A 1998-11-19 2011-04-14 Nukleinsyre som koder for en deletert form av h-parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmåter, vektor, celle, ikke-humant pattedyr samt anvendelse. NO333907B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9814524A FR2786199B1 (fr) 1998-11-19 1998-11-19 Mutations du gene de la parkine, compositions, methodes et utilisations
US12423999P 1999-03-12 1999-03-12
FR9910140A FR2797272B1 (fr) 1999-08-04 1999-08-04 Nouvelles mutations du gene de la parkine, compositions, methodes et utilisations
PCT/FR1999/002833 WO2000031253A2 (fr) 1998-11-19 1999-11-18 Mutations du gene de la parkine, compositions, methodes et utilisations

Publications (2)

Publication Number Publication Date
NO20110582L true NO20110582L (no) 2001-07-18
NO333907B1 NO333907B1 (no) 2013-10-14

Family

ID=27253486

Family Applications (5)

Application Number Title Priority Date Filing Date
NO20012342A NO330896B1 (no) 1998-11-19 2001-05-11 Nukleinsyre som koder for en mutert form av h-parkin, polypeptid, antistoff,sammensetning, probe, fremgangsmater, vektor, celle, ikke-humant pattedyr samt anvendelser.
NO20110582A NO333907B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for en deletert form av h-parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmåter, vektor, celle, ikke-humant pattedyr samt anvendelse.
NO20110578A NO332173B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for humant parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmate, vektor, celle, ikke-humant pattedyr samt anvendelse.
NO20110577A NO332174B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for humant parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmate, vektor, celle, ikke-humant pattedyr samt anvendelse
NO20110580A NO333906B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for en deletert form av h-parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmåter, vektor, celle, ikke-humant pattedyr samt anvendelse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20012342A NO330896B1 (no) 1998-11-19 2001-05-11 Nukleinsyre som koder for en mutert form av h-parkin, polypeptid, antistoff,sammensetning, probe, fremgangsmater, vektor, celle, ikke-humant pattedyr samt anvendelser.

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO20110578A NO332173B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for humant parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmate, vektor, celle, ikke-humant pattedyr samt anvendelse.
NO20110577A NO332174B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for humant parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmate, vektor, celle, ikke-humant pattedyr samt anvendelse
NO20110580A NO333906B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for en deletert form av h-parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmåter, vektor, celle, ikke-humant pattedyr samt anvendelse

Country Status (15)

Country Link
US (3) US8835618B2 (no)
EP (5) EP2311954A1 (no)
JP (1) JP5424519B2 (no)
AT (1) ATE440138T1 (no)
AU (1) AU778281B2 (no)
CA (1) CA2351567C (no)
CY (1) CY1110535T1 (no)
DE (1) DE69941300D1 (no)
DK (1) DK1131424T3 (no)
ES (1) ES2330281T3 (no)
IL (3) IL142755A0 (no)
NO (5) NO330896B1 (no)
NZ (1) NZ512313A (no)
PT (1) PT1131424E (no)
WO (1) WO2000031253A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1081225A1 (en) * 1999-08-30 2001-03-07 Biofrontera Pharmaceuticals GmbH Transgenic animal model for neurodegenerative diseases
WO2001092576A1 (en) * 2000-05-26 2001-12-06 Duke University Methods of screening for parkinson's disease
FR2845245A1 (fr) * 2002-10-07 2004-04-09 Aventis Pharma Sa Modele animal de la maladie de parkinson
US7790390B2 (en) 2004-10-27 2010-09-07 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
US7807465B2 (en) 2004-10-27 2010-10-05 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
CN110295147A (zh) * 2019-07-22 2019-10-01 新乡医学院 一种食管癌细胞系中功能基因敲除后增殖表型的快速鉴定方法及其应用
US12133897B2 (en) * 2020-05-21 2024-11-05 Nysnobio Gt Neurology, Llc Gene therapy delivery of Parkin mutants having increased activity to treat Parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435058T2 (de) * 1993-10-05 2008-04-30 Asahi Glass Co., Ltd. Multicloning-vektor, expressionsvektor und herstellung von fremdproteinen unter verwendung des expressionsvektors
CA2223061C (en) 1995-06-06 2008-04-22 Jan Vijg Method of and apparatus for diagnostic dna testing
DK1063294T3 (da) 1998-02-09 2006-05-22 Boehringer Ingelheim Int DNA'er eller gener der deltager i Parkinsons sygdom
CA2872581C (fr) * 1998-11-19 2018-04-10 Aventis Pharma S.A. Mutations du gene de la parkine, compositions, methodes et utilisations

Also Published As

Publication number Publication date
IL142755A0 (en) 2002-03-10
NO330896B1 (no) 2011-08-08
NO20110577L (no) 2001-07-18
NO332174B1 (no) 2012-07-16
US20150074836A1 (en) 2015-03-12
CY1110535T1 (el) 2015-04-29
NO20012342D0 (no) 2001-05-11
EP1131424A2 (fr) 2001-09-12
PT1131424E (pt) 2009-10-23
DK1131424T3 (da) 2009-11-23
ES2330281T3 (es) 2009-12-07
NO20110578L (no) 2001-07-18
CA2351567C (fr) 2016-01-12
WO2000031253A2 (fr) 2000-06-02
NO332173B1 (no) 2012-07-16
EP2128257A3 (fr) 2010-03-03
US20170183736A1 (en) 2017-06-29
NO333907B1 (no) 2013-10-14
AU1276900A (en) 2000-06-13
WO2000031253A3 (fr) 2000-09-28
US8835618B2 (en) 2014-09-16
EP2128257A2 (fr) 2009-12-02
JP5424519B2 (ja) 2014-02-26
EP2311954A1 (fr) 2011-04-20
NO20012342L (no) 2001-07-18
AU778281B2 (en) 2004-11-25
EP1131424B1 (fr) 2009-08-19
JP2002536961A (ja) 2002-11-05
NO20110580L (no) 2001-07-18
US9540693B2 (en) 2017-01-10
EP2345722A1 (fr) 2011-07-20
CA2351567A1 (fr) 2000-06-02
IL187652A (en) 2010-02-17
DE69941300D1 (de) 2009-10-01
NO333906B1 (no) 2013-10-14
EP2305816A1 (fr) 2011-04-06
ATE440138T1 (de) 2009-09-15
NZ512313A (en) 2003-12-19
IL142755A (en) 2009-08-03
US20120064598A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
NO20110580L (no) Mutasjon av parkingen, preparater, fremgangsmater og anvendelser
Manchenko Handbook of detection of enzymes on electrophoretic gels
Ying et al. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome
Ordway et al. Cysteine 64 of Ref-1 is not essential for redox regulation of AP-1 DNA binding
GB2376018A (en) Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human placenta
ATE391175T1 (de) Multidrug resistenz gen
Nakano et al. Variants in pancreatic carboxypeptidase genes CPA2 and CPB1 are not associated with chronic pancreatitis
JP2003517830A5 (no)
EP0274482A4 (en) Compositions and methods for clones containing dna sequences associated with multidrug resistance in human cells.
Owerbach et al. Inheritance of a parotid secretory protein in mice and its use in determining salivary amylase quantitative variants
Matsubara et al. Mammalian 5-formyluracil− DNA glycosylase. 1. Identification and characterization of a novel activity that releases 5-formyluracil from DNA
Cao et al. Association of matrix metalloproteinase‐1 promoter polymorphism with generalized aggressive periodontitis in a Chinese population
ATE373095T1 (de) Mutierte muskelspezifische enhancer
Su et al. Two novel mutations in the gene encoding thyroxine‐binding globulin (TBG) as a cause of complete TBG deficiency in Taiwan
DE60023691D1 (de) T-bet zusammensetzungen und deren vervendungsmethoden
DE69833104D1 (de) Glaukom diagnose und behandlung
Stevens et al. Clinically Irrelevant Terminal 16q21 Deletion Detected by NIPT Is Attributable to Inherited Fragility at FRA16B
WO2002086113A3 (en) Enzyme and snp marker for disease
CN101240325A (zh) 一种检测遗传基因修复能力的试剂盒
Henry Differentiation of allozyme loci to distinguish between two species of Eisenia
Christensen et al. Characterization of transgenic mice with the expression of phenylalanine hydroxylase and GTP cyclohydrolase I in the skin
Budden et al. S. pombe Rtf2 is Important for Replication Fork Barrier Activity of RTS1 via Splicing of Rtf1
Harris Mutagenicity of chemicals and drugs
Winter Investigation of de novo methylation activity in mutants of the EcoKI methyltransferase
Cortopassi Molecular genetics and evolution of P lysozyme

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees